by The global DNA vaccines market is poised for significant growth, driven by a surge in the prevalence of cancer, infectious diseases, and an ever-evolving landscape of immunology and molecular biology. DNA vaccines, utilizing engineered DNA to stimulate immunologic responses, are emerging as a powerful tool in the fight against a wide range of pathogens, including viruses, bacteria, parasites, and fungi, as well as potential applications in cancer therapy.
Revolutionizing Vaccination Technology
DNA vaccines represent the next frontier in vaccination technology. They offer several advantages, including reduced infection risk, convenient transportation, and room temperature stability. However, challenges such as low immunogenicity in larger animals and humans need to be addressed, necessitating higher DNA doses and optimization of transfection techniques.
Rising Cases of Cancer and Infectious Diseases
The global prevalence of cancer is on the rise, with an estimated 18.1 million cases worldwide in 2020. Therapeutic DNA cancer vaccines are gaining traction as a promising approach to boosting the immune systems response to cancer. As the number of cancer cases continues to increase, the demand for DNA vaccines is expected to surge, further propelling market growth.
Simultaneously, factors such as climate change, urbanization, and shifting land-use patterns raise the risk of infectious diseases, including tuberculosis, COVID-19, and Swine Flu. DNA vaccines encode antigens that evoke robust immune responses, making them a critical tool in combating infectious diseases. With approximately 10 million individuals affected by tuberculosis in 2020, the adoption of DNA vaccines is expected to rise in tandem with the growing incidence of infectious diseases.
Veterinary Hospitals Lead the Way
Veterinary hospitals are set to dominate the DNA vaccines market, driven by an increase in animal disease incidences, rising pet populations, and growing demand for veterinary services. The expansion of the global cattle population and heightened demand for animal products further contributes to the growth of this segment.
North America and Asia Pacific Take Center Stage
North America holds a prominent position in the global DNA vaccines market, driven by rapid advancements in immunology and molecular biology, increasing cases of diseases such as HIV, cancer, and hepatitis, and government investments in DNA vaccines. The regions efforts to combat antibiotic-resistant pathogens also contribute to market growth.
In the Asia Pacific region, investments in DNA vaccine research and development, government support, and well-established healthcare infrastructure are driving market expansion. Clinical studies, particularly for third-generation vaccination technology, are gaining momentum, further boosting the adoption of DNA vaccines.
A Dynamic Competitive Landscape
Leading players in the global DNA vaccines market are forging alliances, collaborations, and partnerships to advance research and development. For instance, in February 2022, Eli Lilly & Company announced a substantial investment in DNA-based research and development. Similarly, in October 2020, Boehringer Ingelheim partnered with Henke-Sass and Wolf to create innovative intramuscular needle-free vaccine injection equipment for pigs.
Key players in the DNA vaccines market include BOEHRINGER INGELHEIM GmbH (Merial), ELI-LILLY (Novartis Animal Health), GeneOne Life Science, GEOVAX LABS, INC, Inovio Pharmaceuticals (VGX Animal Health), Genexine, Inc., VIATRIS INC. (Rottapharm Biotech), ZOETIS INC. (Fort Dodge Animal Health), Takara Holdings (Takara Bio), and Zydus Cadila.
The global DNA vaccines market is on a growth trajectory, driven by innovation, increasing disease burden, and the need for effective, low-cost vaccination solutions. As the world grapples with evolving health challenges, DNA vaccines are emerging as a promising tool in the fight against diseases.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/dna-vaccines-market
Our Blogs:
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of
services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
This press release first seen on Brilad
COMTEX_442085753/2840/2023-10-18T16:49:24
Julian Lopez is professor emeritus of finance, served as the founding academic affairs dean and founding chair of the finance department.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No journalist was involved in the writing and production of this article.